Mersana Therapeutics Profit Margin

The latest profit margin for MRSN is -211.21% as of September 2025. That compares with -214.19% in the prior-year period — up 1.4% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Mersana Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, MRSN's profit margin moved from -214.19% to -211.21% — a 1.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Mersana Therapeutics's valuation or profitability profile.

Against Healthcare companies, MRSN currently prints -211.21% for profit margin, while the sector average sits near 13.89%. That is roughly 1620.6% below the sector mean. Large gaps often invite a closer look at Mersana Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Mersana Therapeutics converts resources into returns. At -211.21%, MRSN may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -214.19% in the prior-year period — up 1.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting MRSN's profit margin (-211.21%), review year-over-year change from -214.19%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.